MARKET WIREStock Titan • 23h ago
A live results call from NeuroPace is set for 1:30 p.m. Pacific on Nov. 12.Stock Titan report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.
Why NPCE Stock advanced +0.33% Today — RQD Quant Desk Flash
$12.34 +0.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $12.32
Neuropace Inc. (NPCE) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $422.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NPCE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NPCE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Neuropace Inc. (NASDAQ: NPCE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $12.34 (+0.33% 1D, market cap $422.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NPCE ranks #967 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NPCE compare to CARL and SI in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), NPCE carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 77.2%, and ROIC of -23.0%. By comparison, CARL (Carlsmed Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $408.2M) and SI (Shoulder Innovations Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -16.1%, cap $398.3M). Among the 5-stock peer group, NPCE leads on earnings multiple (N/A) while CERS leads on capital efficiency (-15.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NPCE?
▼
Per NPCE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001528287), Neuropace Inc. generated $100.0M in revenue (+25.1% YoY), -$21.5M in net income, and -$11.3M in free cash flow against $105.6M in total assets and $58.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $12.32 (-0.13%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (21/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-16.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NPCE)Realized 20D OHLCV Swing Band: ±9.1%
Deterministic 5-Pillar Attribution (21/100 Composite)
🔍 WHY NPCE SCORES 21/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (29% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 77.2% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$12.68+6.5% Next Q
29
Q2 (-2Q)Grade E$13.51-3.6% Next Q
26
Q3 (-1Q)Grade E$13.02-5.2% Next Q
24
CurrentGrade E$12.34-11.6% Hist 90D α
21
Trajectory: E (29) → E (21)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NPCE Turnaround Squeeze
While NPCE currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.62) and Max Pain ($12.96) forces dealer call-delta covering toward $20.58.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NPCE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NPCE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NPCE Stock advanced +0.33% Today — RQD Quant Desk Flash
Neuropace Inc. (NPCE) advanced +0.33% to $12.34, trading at 30% of its 52-week range ($9.22 – $19.6). Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 30% of its 52-week range ($9.22 – $19.6) with RSI-14 at 41.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.1% around $12.34 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 77.2% gross margin and $0 annual free cash flow.
Live NPCE Headlines & Catalysts
MARKET WIREMarketBeat • 1d ago
NeuroPace, Inc. (NPCE) - What Are Brokerages Saying About This Stock?MarketBeat report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 1d ago
NeuroPace (NPCE) Slips to $12.56 as Shares Consolidate Below Resistance - Island Reversalhttps://www.dars.gov.et/ report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
(NPCE) as a Liquidity Pulse for Institutional TacticsStock Traders Daily report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
NeuroPace (NPCE) Projected to Release Earnings on TuesdayMarketBeat report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
NeuroPace Q3 2026 Earnings Date and EstimatesMarketBeat report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 1d ago
NPCE Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares - Upward Estimate Revisionhttps://www.dars.gov.et/ report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026MOUNTAIN VIEW, Calif., October 29, 2026--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NPCE)
- ✓Walkthrough of NPCE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NPCE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.98%🛡️ HOLDING TREND SUPPORT
2026-11-03O $13.01H $13.01L $12.30C $12.34VOL 80.9K
RES: $13.15SUP: $11.70SMA50: $13.62SMA200: $14.94
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NPCE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +25.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on NPCE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NPCE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NPCE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NPCE)
Health Care Rank #967 of 1015
⚔️ CARL vs NPCE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NPCE vs. CARL, SI, BWAY, CERS)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Neuropace Inc. (NPCE) ranks #967 by composite RQD confidence (21/100, grade E) and #465 by equity capitalization ($422.2M). Within this direct 5-issuer industry benchmark cohort, NPCE leads on earnings valuation at N/A trailing P/E, while CERS leads on capital efficiency and profitability with -15.5% ROIC and — gross margin. SI currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with NPCE at 21/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NPCE
ACTIVE
Neuropace Inc. | E | 21/100 | — | 77.2% | -23.0% | +0.33% | $422.2M | Benchmark Subject |
| CARL Carlsmed Inc. | D- | 38/100 | — | 75.3% | -35.0% | +0.47% | $408.2M | /carl-vs-npce → |
| SI Shoulder Innovations Inc. | D | 44/100 | — | 76.5% | -16.1% | +0.99% | $398.3M | /si-vs-npce → |
| BWAY BrainsWay Ltd. | D | 44/100 | — | — | — | -2.38% | $455.9M | /bway-vs-npce → |
| CERS Cerus Corporation | E | 27/100 | — | — | -15.5% | +3.51% | $459.5M | /cers-vs-npce → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001528287 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neuropace Inc. (NPCE) reported GAAP revenue of $100.0M (+25.1% vs. FY2024 revenue of $79.9M , and +52.8% cumulative change since FY2023) , GAAP net income of -$21.5M, operating cash flow of -$11.0M, and free cash flow of -$11.3M (+37.9% YoY). On the balance sheet, NPCE closed FY2025 with $105.6M in total assets against $58.9M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $100.0M | -$21.5M | -$11.0M | -$11.3M | $105.6M | $58.9M |
| FY2024 (FY) | 2024-12-31 | $79.9M | -$27.1M | -$17.9M | -$18.3M | $94.6M | $59.5M |
| FY2023 (FY) | 2023-12-31 | $65.4M | -$33.0M | -$19.7M | -$19.7M | — | — |
3. NPCE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NPCE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Neuropace Inc. (NASDAQ: NPCE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $12.34 (+0.33% 1D, market cap $422.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NPCE ranks #967 in composite RQD confidence.
How does NPCE compare to CARL and SI in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), NPCE carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 77.2%, and ROIC of -23.0%. By comparison, CARL (Carlsmed Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $408.2M) and SI (Shoulder Innovations Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -16.1%, cap $398.3M). Among the 5-stock peer group, NPCE leads on earnings multiple (N/A) while CERS leads on capital efficiency (-15.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NPCE?
Per NPCE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001528287), Neuropace Inc. generated $100.0M in revenue (+25.1% YoY), -$21.5M in net income, and -$11.3M in free cash flow against $105.6M in total assets and $58.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NPCE trading relative to its 50-day, 200-day, and 52-week technical levels?
NPCE last traded at $12.34 (+0.33% on volume of 120,470 shares), positioning the stock -9.40% below its 50-day simple moving average ($13.62) and -17.40% below its 200-day simple moving average ($14.94). Across its 52-week range of $9.22 to $19.60, NPCE sits at the 30.1% percentile with a 14-day RSI of 41.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.1% ($11.22 to $13.46).
ROARABLE RATING BRIEF • RQD 21/100 (E)
✓ SEC XBRL & RQD VERIFIED
NPCE — Neuropace Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Neuropace Inc. (NPCE) earns a live Roarable RQD composite score of 21/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $12.34 (+0.33% 1D, market capitalization $422.2M).
- Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -23.0%, gross margin of 77.2%, operating margin of -16.3%, and free cash flow yield of -2.54%.
- Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (3/20) + Forensic Balance Sheet (6/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 5/9, and Debt/Equity of 3.09x.
2. Business Model, Unit Margins & SEC Financial Trajectory
. Is a NASDAQ-listed issuer in the Health Care sector and Medical/Dental Instruments industry, with a market capitalization of $0.4B. Per the market data, the company reports a gross margin of 77.2%.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Neuropace Inc. (NPCE) reported $100.0M in annual revenue (up from $79.9M in FY2024, +25.1% YoY) and -$21.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($65.4M revenue, -$33.0M net income) through FY2025, NPCE scaled operating cash flow to -$11.0M and free cash flow to -$11.3M, backed by $105.6M in total assets against $58.9M in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 21/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.54% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $9.22 – $19.60 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -16.3% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
A prospective investor should note that the leverage indicated by Debt/Equity of 3.
- Key Question #1: Can NPCE sustain or expand its -16.3% operating margin and -23.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $100.0M and free cash flow of -$11.3M, how will capital allocation balance growth reinvestment against $58.9M in total debt?
- Key Question #3: How sensitive is NPCE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
NPCE Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Neuropace Inc. (NPCE) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stock Titan • 23h ago
A live results call from NeuroPace is set for 1:30 p.m. Pacific on Nov. 12. Stock Titan report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
NeuroPace, Inc. (NPCE) - What Are Brokerages Saying About This Stock? MarketBeat report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago
NeuroPace (NPCE) Slips to $12.56 as Shares Consolidate Below Resistance - Island Reversal https://www.dars.gov.et/ report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
(NPCE) as a Liquidity Pulse for Institutional Tactics Stock Traders Daily report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
NeuroPace (NPCE) Projected to Release Earnings on Tuesday MarketBeat report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
NeuroPace Q3 2026 Earnings Date and Estimates MarketBeat report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago
NPCE Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares - Upward Estimate Revision https://www.dars.gov.et/ report covering Neuropace Inc. (NPCE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 4d ago
NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026 MOUNTAIN VIEW, Calif., October 29, 2026--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NPCE Bull vs. Bear Conversation Board — What's Your Call at $12.34?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NPCE 🐻 33% BEARISH CONVICTION
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH
🎯 Target: $15.38 (+25.0%)
📌 Pinned Debate Revenue grew from $65.4M in FY 2023 to $100.0M in FY 2025 while the operating loss narrowed from -$27.2M to -$16.3M.
Don't sleep on NPCE's setup in Health Care. Revenue grew from $65.4M in FY 2023 to $100.0M in FY 2025 while the operating loss narrowed from -$27.2M to -$16.3M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (21/100) backs up the fundamental quality.
SectorRotator 🐂 BULL
@MidwestValue Agree on the RQD 21/100 quality, though with 1.0 beta I'm scaling in with half-size at $12.30 and keeping dry powder in case we test $11.44.
RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH
🎯 Target: $9.84 (-20.0%)
Spot @ $12.30 ROIC of -23%, FCF yield of -2.54%, Altman Z of 0.2, and Debt/Equity of 3.09 together signal forensic and cash-generation risk.
I respect the product at Neuropace Inc., but the stock at $12.30 is a different story. ROIC of -23%, FCF yield of -2.54%, Altman Z of 0.2, and Debt/Equity of 3.09 together signal forensic and cash-generation risk.. FCF yield is -2.54% and RQD sits at 21/100 (E) — why pay up here when you can wait for next quarter's numbers?